Savara Inc. Faces Class Action Lawsuit Over Securities Fraud Allegations

Investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, inclusive, are encouraged to contact the Schall Law Firm before November 10, 2025, to discuss their rights and potential recovery of losses. The class action lawsuit alleges that Savara made false and misleading statements to the market regarding its BLA for MOLBREEVI, which failed to provide the FDA with adequate information on chemistry, controls, and manufacturing. This led to delays in the approval process, causing the company to potentially require additional capital. As a result, investors suffered damages when the truth about Savara was revealed.

Key Takeaways:

• The class action lawsuit is against Savara Inc. for alleged securities fraud violations of úú10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
• The lawsuit specifically targets investors who purchased Savara securities between March 7, 2024, and May 23, 2025, inclusive.
• The complaint alleges that Savara's BLA for MOLBREEVI failed to provide the FDA with adequate information on chemistry, controls, and manufacturing, making the Company's public statements false and materially misleading.
• The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
• Brian Schall of the Schall Law Firm can be contacted at 310-301-3335 for a free consultation.
• Investors can also contact the firm through their website at or by email at bschall@schallfirm.com.

Statistics:

• The class period spans from March 7, 2024, to May 23, 2025, inclusive.
• The deadline to contact the Schall Law Firm is November 10, 2025.
• Savara's securities are listed on NASDAQ under the ticker symbol.

Sources:

• The Schall Law Firm
• SEC.gov
• NASDAQ.com